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1. INTRODUCTION
The subject of medicinal chemistry explains the design and production of compounds
that  can  be  used  for  the  prevention,  treatment  or  cure  of  human  and  animal  diseases.
Medicinal  chemistry  includes  the  study  of  already  existing  drugs,  of  their  biological
properties and their structure-activity relationships [1]. Medicinal chemistry was defined by
IUPAC  specified  commission  as  it  concerns  the  discovery,  the  development,  the
identification and the interpretation of the mode of action of biologically active compounds at
the molecular level.
 1.1.Medicinal chemistry covers the following stages
• In the first stage new active substances or drugs are identified and prepared from natural
sources,  organic chemical  reactions or biotechnological  processes.  They are known as
lead molecules.
• The second stage is optimization of lead structure to improve potency, selectivity and to
reduce toxicity.
• Third stage is development stage, which involves optimization of synthetic route for bulk
production and modification of pharmacokinetic and pharmaceutical properties of active
substance to render it clinically useful.
Medicinal chemistry is the application of chemical research techniques to the synthesis of
pharmaceuticals. During the early stages of medicinal chemistry development, scientists were
primarily concerned with the isolation of medicinal agents found in plants. Today, scientists
in this field are also equally concerned with the creation of new synthetic  compounds as
drugs. Medicinal chemistry is almost always geared toward drug discovery and development
[2].
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Medicinal  chemists  apply their  chemistry training to  the  process  of  synthesizing new
pharmaceuticals. They also work on improving the process by which other pharmaceuticals
are made. Most chemists work with a team of scientists from different disciplines, including
biologists,  toxicologists,  pharmacologists,  theoretical  chemists,  microbiologists,  and
biopharmacists. Together this team uses sophisticated analytical techniques to synthesize and
test  new drug products and to develop the most cost-effective and eco-friendly means of
production.   Man is slightly nearer to the atom than the stars. From his central position he
can  survey  the grandest  works  of  Nature  with  the   astronomer  or  the minutest  with  the
chemist.
Heterocyclic  chemistry is  the chemistry branch dealing exclusively with synthesis,
properties and application of heterocyclic.  A  Heterocyclic compound is defiend  as  any
organic compound where their molecules are characterized by  rings  containing  at least one
atom other than carbon and hydrogen. Such as sulfur, oxygen or nitrogen as part of the ring.
The word  “hetero”  means  “  different  from carbon  and  hydrogen  ’’.  Many hetero  cyclic
compounds are biosynthesized by plants and animals and they are biologically active. Some
hetero  cyclic  compounds  are  fundamentals  of   life  like,  haeme  derivatives  in  blood  and
chlorophyll  is  essential  for  photosynthesis  in  plants.  Several  hetero  cycles  are  the  basic
structure nucleus for nicotine ,pyridoxine, cocaine, morphine etc., They may be either simple
aromatic  ring  or  non-aromatic  rings.  Some  heterocyclic  compounds  are  known  as
carcinogens. Researchers have show that heterocyclic amines are the carcinogenic chemicals.
Among the family of heterocyclic compounds, nitrogen containing heterocyclic especially
Quinazolines  show  a  number  of  biological  activities:  antimicrobial,  anti-inflammatory,
analgesic, anticonvulsant, antiulcer, anticancer, anti tubercular activity, antihypertensive [3].
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1.2. QUINAZOLINE
Quinazoline  is  a  compound made up of  two fused  six   member simple aromatic  rings-
benzene  and   pyrimidine   ring.  Medicinally  it  is  used  as  antimalarial  agent.  It  was  first
prepared by Gabriel in 1903 and first isolated from the Chinese plant aseru. The development
of research on biological activity of quinazoline compounds started when the compound 2-
methyl-1,3-aryl-4-quinazoline derivative was synthesized.  This compound has soporific &
sedative action.  In last 10 to 15 years of research for medicinal has been characterized by
significant advances.
In  1968 only two derivatives were used methaqualone and diuretic quinathazone. In  1980
about 50 kinds of the quinazolines were derived with various kinds of disease. 
In  1869  Griess  prepared  the  first  quinazoline  derivative,  2–cyano-3,4-dihydro-4-
oxoquinazoline,  by  the  reaction  of  cyanogens  with  anthranilic  acid.  Griess  apparently
recognized the bicylic nature of the product which he called bicyanoamido benzoyl and used
this name until 1885.
                                                
NH
N CN
O
The preparation of the parent quinazoline came many years later when Bischler and Lang
obtained it by decarboxylation of the 2-carboxy derivative.
A more satisfactory synthesis of quinazoline was subsequently devised by Gabriel in 1903
that studied properties and those of its derivatives in greater detail [4].
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The name was proposed by Widdege. Other names such as phenmiazine, benzyleneamidine,
benzo-1, 3-diazine, 5, 6-benzopyrimidine and 1, 3-diazanapthaline have occasionally been
used. The numbering suggested by Paal and Busch is still in use. The presence of a fused
benzene  ring  alters  the  properties  of  the  pyrimidine  ring considerably.  The  two nitrogen
atoms are not equivalent, and the marked polarization of the 3, 4- double bond is reflected in
the reactions of quinazoline [5]. The properties of substitute’s quinazolines depend largely on
• The nature of the substitutents.
• Whether they are in the pyrimidine ring (or) in the benzene ring. 
• Whether (or) not complete conjugation is present in the pyrimidine ring.
The chemistry of quinazoline was reviewed by Williamson in 1957, then by Lindquist in
1959 and brought up to date by Armarego in 1963.
1.2.1. Chemical Properties
Quinazoline is stable in cold, dilute acid and alkaline solutions, but it is destroyed when these
solutions  are  boiled.  O-Aminobenzaldehyde,  ammonia  and  formic  acid  are  formed when
quinazoline is boiled with hydrochloric acid.
1.2.2. Hydrolysis, oxidation and reduction
Oxidation of quinazoline in dilute aqueous acid, with two equivalents of hydrogen peroxide
at room temperature gave a high yield of 3, 4- dihydro-4-oxo quinazoline.
In alkaline medium, where the anhydrous neutral species of quinazoline were predominantly
undergoing oxidation with KMnO4  furnished a high yield of 3, 4-dihydro-4-oxo quinazoline
was also formed [6].
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Catalytic  hydrogenation  of  quinazoline  stopped  after  the  absorption  of  one  molecules  of
hydrogen and gave 3, 4-dihydro quinazoline.
Reduction  with  sodium  amalgam  gave  1,2,3,4-tetrahydroquinazoline.  Lithium  aluminum
hydride and sodium borohydride gave 3,4-dihydro and 1,2,3,4-tetrahydroquinazoline.
1.2.3. Nucleophilic and electrophilic substitution reactions
The two known nucleophilic substitution reactions of quinazoline namely with sodamide and
hydrazine, presumably proceed via the intermediate addition products and gave 4-amino and
4-hydrazine quinazoline.
Nitration is  the only known electrophilic  substitution reaction  of  quinazoline.  Theoretical
considerations show that the expected order of reactivity is at positions 8 > 6 > 5 > 7 > 4 > 2.
Quinazoline  gives  6-nitroquinazoline  with  fuming  nitric  acid  in  concentrated  H2SO4.  No
oxidation of  the heterocyclic  ring can occur under these conditions because the hydrated
cation is not present [7].
Conc.HNO3N
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1.2..4. Alkylation reactions
Alkylation  of  quinazoline  takes  place  on  N,  3-methyl,  3-ethyl-3-alkyl  and  3-benzyl
quinazolinium salts  readily  take  up  a  molecule  of  alcohol  to  form the  corresponding  4-
alkoxy-3-alkyl-3,4-dihydro quinazolinium salts. These salts yield the pseudo bases, 3-alkyl-3,
4-dihydro-4-hydroxy quinazolines on treatment with strong alkali.
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1.2.5. Addition Reactions
Quinazoline  is  very  reactive  towards  anionid  reagents  which  attack  position  4.
Sodium bisulphate, hydrogencyanide, acetophenone, acetone, 2- butanone and cyclohexanone
add across the 3,4-double bond of quinazoline. Methyl, ethyl, isopropyl, benzyl, t-butyl and
phenyl magnesium halides and phenyl lithium also add across the 3, 4-double bond to give
the corresponding 4-substituted 3, 4-dihydroquinazolines [8]
1.2.6. Synthesis
Following methods were reported for the synthesis of oxoquinazolines.
Niementowski’s Synthesis
Niementowski’s found that 3 (or) 4 substituted anthranilic acid when reacted with formamide
at 125 - 130ºC for 4 hours gave 86% yield of 3, 4-dihydro-4-oxoquinazoline
6
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Grimmel, Guinther and Morgan’s synthesis
3 moles of O-amino benzoic acids, when heated with 3 moles of an amine together with one
mole  of  phosphorous  trichloride  in  toluene  for  two  hours,  gave  high  yields  of  2,  3-
disubstituted 3,4-dihydro-4-oxoquinazoline
From Isatoic Anhydride
Isatoic  anhydride  readily  reacts  with  equimolar  quantity  of  amines  to  dihydro-4-
oxoquinazolines  by  refluxing  ethyl  orthoformate  for  1-  6hours  without  isolating  the
intermediate amides.
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From 3, 1, 4-Benoxazones (Acylanthranils) and amines.
3,  1,  4-Benoxazones  react  with  amines  to  give  3,  4-dihydro-4-oxoquinazolines.  Primary
aliphatic amines and anilines react with 2-methyl-5-nitro-4-oxoquinazolines.
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From ethyl 2-acetamido-5-nitrobenzoate
 Ethyl 2-acetamido-5-nitrobenzene and alcoholic ammonia when heated in a sealed tube at
170oC yields 3,4-dihydro-methyl-6-nitro4-oxoquinazoline.
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Ethyl 2-acetamido-5-nitrobenzene and alcoholic ammonia when heated in a sealed tube at 
170ºC, yields 3,4-dihydro –methyl-6-nitro-4-oxoquinazoline.
COOC2H5
NHCOR NHCOR
N
N
O
Alcoholic
R' - NH2
NHR'
O
R
R'
Sen and Ray’s synthesis
Boiling a solution of normal (or) isobutyrylanilides with urethane and phosphorous pentoxide
in xylene gave 2-propyl and 2-isopropyl-3, 4-dihydro-4-oxoquinazolines.
NHCOR'
R NH
N
H
O
O
R
H2NCOOC2H5,P2O5
Xylene, 3 - 5 hrs
(R = Me, OMe, OEt; R’ = Me, Et, Pr, Iso-Pro, Ph)
Following methods were reported for the synthesis of 2,4-dioxoquinazolines.
From anthranilic acid and urea
The fusion of anthranilic acid with urea to give 1,2,3,4-tetrahydro-2,4-dioxoquinazoline was
first described by Griess.
COOH
NH2
R NH
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Urea
From O-ureidobenzoic acid
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O-ureidobenzoic  acids  are  readily  prepared  from  the  corresponding  anthranilic  acid  and
potassium  cyanate.  The  ureido  acids  are  then  easily  cyclised  to  the  respective  1,2,3,4-
tetrahydro-2,4-dioxoquinazolines  by  heating  with  acid  (or)  alkali.  Anthranilic  esters  and
amides as well as undergo this reaction.
COR'
NH2
COR'
NHCONH2
NH
N
H
O
O
KNCOR
R
From O- ethoxy carbonyl amino benzoic esters (or) amides
When O-ethoxy carbonyl  amino benzamide and its 4-methyl  derivatives are heated above
their melting points, they lose water and from 1, 2, 3, 4-tetrahydro-2, 4-dioxoquinazoline
COOR
NH2
COOR
NHCOOEt
ClCOOEt RNH2
CONHR
NHCOOEt
NR
N
H
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O
-EtOH
From phthalic acid derivatives
The use of derivatives of phthalic acid for the preparation of dioxoquinazoline necessitates
rearrangement  of  the  Hoffmann  curties  (or)  Lossan  type.  Reaction  of  phthalamide  (or)
phthalimide, N-methyl and N-ethyl phthalimide with alkali hypobromite gives the 1, 2, 3, 4-
tetrehydro 2, 4-dioxoquinazoline.s
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From Isatins
α-isatin oxime rearranges to 1,2,3,4-tetrahydro-2,4-dioxoquinazoline on heating with dilute
sodium hydroxide, β-imino derivatives of isatin, on the other hand, require oxidation with
hydrogen peroxide in alkaline solution in order to from the dioxoquinazoline.
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1.3. MOLECULAR DOCKING
In  the  field  of  molecular  modeling,  docking  is  a  method  which  predicts  the  preferred
orientation of one molecule to a second when bound to each other to form a stable complex.
Knowledge  of  the  preferred  orientation  in  turn  may  be  used  to  predict  the  strength  of
association or binding affinity between two molecules using for example scoring functions.
Docking  is  frequently  used  to  predict  the  binding  orientation  of  small  molecule  drug
candidates to their protein targets in order to in turn predict the affinity and activity of the
small molecule. Hence docking plays an important role in the rational design of drugs. 
1.3.1. Autodock 
Auto  dock  4  is  a  suite  of  automated  docking  tools.  It  is  designed  to  predict  how small
molecules, such as substrates or drug candidates, bind to a receptor of known 3d structure. 
1.3.2. Auto dock 4 comprises three major improvements.
• The docking results are more accurate and reliable.
• It can optionally model flexibility in the target macromolecule.
• It enables Auto dock’s use in evaluating protein – protein interactions.
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1.3.3. Applications 
A binding interaction between a small molecule ligand and a enzyme protein may result in
activation or inhibition of the enzyme. If the protein is a receptor, ligand binding may results
in agonism or antagonism. Docking is most commonly used in the field of drug design – most
drugs are small organic molecules, and docking may be applied to:
 Hit identification – docking combined with a scoring function can be used to quickly
screen large databases of potential drugs in silico to identify molecules that likely to
bind to protein target of interest.
 Lead optimization – docking can be used to predict in where and in which relative
orientation a ligand binds to protein. This information may in turn be used to design
more potent and selective analogs [9]. 
1.4.DRUG LIKENESS
Drug likeness is a qualitative concept used in drug design“dfor how “druglike” a substance is
with respect to factors like bioavailability. It is estimated from the molecular structure before
the substance is even synthesized and tested. A druglike molecule has properties like this
• Optimal solubility to both water and fat, because an orally administered drug has to go
through the intestinal  lining,  carried  in aqueous blood and penetrate  the lipid cellular
membrane to reach the inside of a cell. The model compound for the cellular membrane is
octanol the logarithm of the octanol/water partition coefficient, known  as  ClogP, is used
to estimate solubility. 
• Since the drug is transported in aqueous media like blood and intracellular fluid, it has to
be sufficiently water-soluble. Solubility in water can be estimated from the number of
hydrogen  bond  donors  vs.  alkyl  side  chains  in  the  molecule.  Low  water  solubility
translates to slow absorption and action. Too many hydrogen bond donors, on the other
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hand, lead to low fat solubility, so that the drug cannot penetrate the cell wall to reach the
inside of the cell. 
• Molecular weight:  the smaller, the better, because diffusion is directly affected. 80% of
traded drugs have molecular weights under 450 daltons; they belong to the group ofsmall
molecules. Substructures that have known pharmacological properties. Also, other factors
such as substructures with known toxic, mutagenic or teratogenic properties affect  the
usefulness of a designed molecule. In fact, several  poisons have a good drug likeness.
Natural toxins are used in pharmacological research to find out their mechanism of action,
and if it could be exploited for beneficial purposes. 
• Drug likeness indexes are inherently limited tools. Drug likeness can be estimated for any
molecule,  and  does  not  evaluate  the  actual  specific  effect  that  the  drug  achieves
(biological activity) .Furthermore, first-pass metabolism which is biochemically selective,
can destroy the pharmacological activity of a compound despite good drug likeness. Drug
likeliness was calculated based on “Lipinski’s rule of five". The score is computed using
many commercial and academic softwares like Molinspiration etc [10].
1.4.1. Lipinski's Rule of Five [11]
Lipinski's Rule of Five is a rule of thumb to evaluate druglikeness or determine if a  chemical
compound with a certain pharmological or biological activity has properties that would make
it a likely orally active drug in humans. The rule was formulated by Christopher A.Lipinski in
1997, based on the observation that most medication drugs are relatively small and lipophillic
molecules. 
The rule describes molecular properties important for a drug's pharmacokinetics in the human
body,  including their  absorption,distribution,metabolism,  and  excretion("ADME").  However,
the rule does not predict if a compound is pharmacologically active.
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The rule is important for drug development where a pharmacologically active lead structureis
optimized step-wise for increased activity and selectivity, as well as drug-like properties as
described by Lipinski's rule. The modification of the molecular structure often leads to drugs
with higher molecular weight, more rings, more rotatable bonds and a higher lipophilicity.
1.5.HEPATIC DISEASES
Liver disease is any disturbance of liver function that causes illness. The liver is responsible
for many critical functions within the body and should it become diseased or injured, the loss
of those functions can cause significant damage to the body. Liver disease is also referred to
as hepatic disease. Liver disease is a broad term that covers all the potential problems that
may occur to cause the liver to fail to perform its designated functions. Usually, more than
75% or three quarters of liver tissue needs to be affected before decrease in function occurs
The liver the largest solid organ in the body; and is also considered a gland because among its
many functions, it makes and secretes bile. The liver is located in the upper right portion of
the abdomen protected by the rib cage. It has two main lobes that are made up of tiny lobules.
The liver cells have two different sources of blood supply. The hepatic artery supplies oxygen
rich blood that is pumped from the heart, while the portal vein supplies nutrients from the
intestine and the spleen.
Normally, veins return blood from the body to the heart, but the portal vein allows chemicals
from the digestive tract to enter the liver for "detoxification" and filtering prior to entering the
general circulation. The portal vein also efficiently delivers the chemicals and proteins that
liver cells need to produce the proteins, cholesterol, and glycogen required for normal body
activitiess
1.5.1. Infectious hepatitis
The  term  "hepatitis"  means  inflammation,  and  liver  cells  can  become  inflamed
because of infection.
13
Hepatitis A  is a viral infection that is caused primarily through the fecal-oral route when
small amounts of infected fecal matter are inadvertently ingested. Hepatitis A causes an acute
inflammation of the liver which generally resolves spontaneously. The hepatitis vaccine can
prevent this infection.
Hepatitis B  is spread by exposure to body fluids (needles from drug abusers, contaminated
blood, and sexual contact) and can cause an acute infection, but can also progress to cause
chronic  inflammation  (chronic  hepatitis)  that  can  lead  to  cirrhosis  and  liver  cancer.  The
hepatitis B vaccine prevents this infection.
 Hepatitis C causes chronic hepatitis. An infected individual may not recall any acute illness.
Hepatitis C is spread by exposure to body fluids (needles from drug abusers, contaminated
blood, and sexual contact). Chronic hepatitis C may lead to cirrhosis and liver cancer. At
present, there is no vaccine against this virus.
Hepatitis D is a virus that requires concomitant infection with hepatitis B to survive, and is
spread via body fluid exposure (needles from drug abusers, contaminated blood, and sexual
contact). 
Hepatitis E is a virus that is spread via contaminated food and water exposure.
1.5.2. Treatment for liver disease
Each  liver  disease  will  have  its  own  specific  treatment  regimen.  For  example,
hepatitis A requires supportive care to maintain hydration while the body's immune system
fights and resolves the infection. Patients with gallstones may require surgery to remove the
gallbladder. Other diseases may need long-term medical  care to control and minimize the
consequences of their disease
In patients with cirrhosis and end-stage liver disease, medications may be required to
control the amount of protein absorbed in the diet. The liver affected by cirrhosis may not be
able to metabolize the waste products, resulting in elevated blood ammonia levels and hepatic
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encephalopathy. Low sodium diet and water pills (diuretics) may be required to minimize
water retention.
In  those  with  large  amounts  of  ascites  fluid,  the  excess  fluid  may  have  to  be
occasionally  removed  with a  needle  and  syringe  (paracentesis).  Using local  anesthetic,  a
needle is inserted through the abdominal wall and the fluid withdrawn [12].
Some Marketed available quinazoline derivatives.
1.Prazosin
Chemical Name : 2-[4-furoyl ) piperazine-1-yl]-6,7-dimethoxy quinazolin-4-amine
 Use : Sympatholytic , Treatment of high Blood pressor.
Another Name : Minipress , vasoflex , pressin and Hypovase.
  2.Gefitinib
 Chemical Name : N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-yl-
                                        propyl) quinazolin-4-amine
   Use  : In the treatment of certain type of cancer , EGFR inhibitor 
 Another Name  : Astra Zeneca
3.Erlotinib
Chemical Name : N-(3-ethnyl phenyl )-6,7-bis(2-methoxy ethoxy) quinazolin-4-amine
Use  : In the Treatment of Pancreatic cancer, Lung cancer inhibitor of 
EGFR , thyrosine kinase  inhibitor. 
4.Tetrodotoxin (TTX)
Chemical Name    :  ( 4R , 4aR , 5R , 6S , 7S , 8S , 8aR , 10S , 12S )-2-azaiumylidene-
4,6,7,12-tetrahydroxy-6-(hydroxyl methyl)-2,3,4,4a,5,6,7,8-octahydro-
1H-8a,10-methano-5,7-epoxy methanoxy)quinazolin-10-olate.
Use  :  Potent neurotoxin
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5. Alfuzosin
Chemical Name :  N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-   
amino]propyl]- tetrahydra furan-2-carboxamide.
Use : alpha-1 receptor antagonist , Benign Hyper Prostatic   
Hyperplasia(BPH)
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       2. OBJECTIVE AND PLAN OF WORK
The synthesis of Tetrahydroquinazoline  and their derivatives has been of considerable 
interest to organic and medicinal chemists for many years as indicated by large number of 
drugs. Tetrahydroquinazoline show a number of biological activities: like,
    (1) Antimicrobial (2) Anticonvulsant (3) Anti-inflammatory  etc.
The molecular manipulation of promising lead compound is still a major line of approach for
the discovery of new drugs. Molecular manipulation involves the efforts to combining the
separate groups having similar activity in one compound. Thus by making gradual changes in
the physico-chemical properties of the drug and thus the biological activity of the compound.
Combination of two or more moieties into one is a common procedure of manipulation and
this can probably result in the increase of biological activity and removal of untoward side
effects. It is my effort in the present work to synthesize tetrahydroquinazoline derivatives by
using different aldehydes.
2.1. Steps involved in plan of work
Synthesis and Characterization
• Synthesis of title compounds.
• Study of physico-chemical properties of the synthesized compounds.
• Spectral Studies.
The chemical structure of the synthesized compounds were characterized by means of IR,
1H-NMR, Mass spectral  study.
2.2. Biological screening
To evaluate the in vitro  hepatoprotective activity of the title compounds.
                          
            3. REVIEW OF LITERATURE
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1. Won-Jea C et al.,  have studied the virtual screening was employed for hit compound
identification with chemical libraries using Surflex Dock. Subsequently, hit optimization
for potent and selective candidate JAK2 inhibitors was performed through synthesis of
diverse C-1 substituted quinazoline derivatives [13].
2. Rajveer CH et al.,  have been synthesized a number of substituted oxoquinazolines &
reported their analgesic & anti-bacterial activity [14].
3. Vouy LT and Michelle M  et al., has done the Condensation of o-iodobenzaldehydes
with amidine hydrochlorides  under  ligand-free  copper catalyzed Ullmann N-arylation
conditions afforded the corresponding quinazolines in good to excellent yield [15].
4. Patil JP et al., reported the synthesis of  2-methyl-3(H)-Quinazolinone by microwave 
irradiation method [16].
5. Florea  Dumitrascu et  al.,  have  been  synthesized  pyrrol  (1,2-c)quinazoline  and
investigated using X-ray diffraction and  their NOE experiments in high resolution NMR
[17].
6. Deepti Kohli et al., have been synthesized quinazolinone derivatives and evaluated for
their antibacterial activity by cup plate method by measuring inhibition zone [18].
7. Talersa GL et al.,  have been treated  the  benzoxazine 1 with hydrazine hydrate in
ethanol furnished 3 amino-2-phenylquinazolin-4-(3H)-one 2, which upon condensation
with aldehydes yielded the corresponding 3-arylidenoamino derivatives. Cyclization of
these derivatives using mercaptosuccinic acid afforded 1, 3-thiazolidin-4-one ethanolic
acids,  which after  esterfication with N-hydroxyphthalimide or N-hydroxysuccinamide
via acid chlorides produced the respective ethanolic esters [19].
8. Salahuddin MD et al.,  have been synthesized a series of novel  3-(6-substituted-1,  3-
benzothiazole-2-yl)-2-[{(4-substituted  phenyl)   amino}  methyl]   quinazoline-4(3H)-
ones and the  synthesized  quinazoline-4-one  derivatives  were  investigated  for  their
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anti-inflammatory and antibacterial activity [20].
9. Olayinka O. Ajani et al.,  have been synthesized  a series of novel quinoxalin-2(1H)-
one-3-hydrazone  derivatives,  2a  -  8d  were  synthesized  via  condensation  of  3
hydrazinoquinoxalin-2(1H)-one,  with  the  corresponding  ketones  under  microwave
irradiation.  The  microwave  assisted  reaction  was  remarkably  successful  and  gave
hydrazones  in  higher  yield  at  less  reaction  time  compared  to  conventional  heating
method [21].
10. Chandrasekara  Reddy  G et  al., have  done  the  docking  studies  of  few  newly
synthesized  6,7-dialkoxy-4-anilinoquinazoline  derivatives  which   showed  EGFR-TK
inhibitory  [22].
11. Gazi Irez et al., have been synthesized (hydroxyimino) (2-phenyl(1,2,3,4
tetrahydroquinazolin-2-yl))methane  and  (hydroxyimino)(2-(2-thienyl)(1,2,3,4-
tetrahydroquinazolin-2-yl))methane  were  synthesized  by  the  condensation  of  2-
(hydroxyimino)-1-phenylethan-1-one  and  2-(hydroxyimino)-1-(2-thienyl)ethan-1-one
with  2-aminobenzylamine  (2-ABA).  Complexes  of  these  ligands  with  Co3+were
prepared  with  a  metal:  ligand  ratio  of  1:2.  The  ligands  and  their  complexes  were
elucidated on the basis of elemental analyses, AAS, FT-IR, 1H- and13C-NMR spectra,
mass spectra, magnetic susceptibility measurements, molar conductivity [23].
12. Varsha  Jatav  et  al., have  been  synthesized  3-[5-(4-  substituted  phenyl)-1,  3,  4-
thiadiazole-2-yl]-2-styryl  quinazoline -4(3H)-ones and reported their antibacterial  and
antifungal activity [24].
13. Varsa Jatav  et al., have been synthesized 3-[5-substituted-1, 3, 4-thiadiazole-2-yl]-2-
styryl quinazoline-4(3H)-ones and their CNS depressant activity was screened with the
help of forced swim pool method [25].
14. Yuliang Wang et al., have designed and synthesized series of 4-(2-methoxyphenyl)-2-
oxobutylquinazoline derivatives and reported their anticoccidial activity [26].
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15. Praveen  Kumar  P  et  al., have  been  synthesized  6,7,8,9-tetrahydro-5(H)-5-
nitrophenylthiazolo[2,3-b]-quinazolin-3(2H)-one  derivatives  and  the  synthesized
compounds have been screened for antimicrobial activity [27].
16. Omar Abd el-Fattah M. Fathalla et al., have been synthesized the  new series of some
2-[(E)-2-furan-2-yl-vinyl]-quina-  zolin-4(3H)-ones  incorporated  into  pyrazoline,
isoxazoline,  pyrimidine  or  pyrimidine-thione  ring  systems  at  position-3  of  the
quinazoline  ring.  The antimicrobial  activity and  anti-inflammatory effect  of  some of
these compounds were studied [28].
17. Omar Al-Deeb et al., have been synthesized  a series of 21 new 2-alkylthio-6-iodo-3-
substituted-quinazolin-4-one derivatives  was prepared and screened for their  in vitro
antitubercular  activity  against  Mycobacterium  tuberculosis strain  HRv,  using  the
radiometric BACTEC 460-TB methodology [29].
18. Siddappa  K  et  al., have  been  synthesized  3-[(2-Hydroxy-quinolin-3-ylmethylene)-
amino]-2-phenyl- 3H-quinazolin-4-one and its Metal (II) Complexes and reported their
antimicrobial activity [30].
19. Cedric Loge et al., have done  Continuous efforts in microwave-assisted synthesis and
the  structure  activity  relationships’  (SARs)  studies  of  novel  modified  9-oxo-thia-
zolo[5,4-f]quinazoline-2-carbonitriles,  allowed  identification  of  new  amidine  and
imidate derivatives  as potent and dual CDK1/GSK-3 inhibitors.  Combination of lead
optimization  and  molecular  modeling  studies  allowed  identification  of  a  dual
CDK1/GSK-3 inhibitor (compound 13d) with submicromolar values [31].
20. Gloria D Galarce  et al.,  This study describes the effect  of novel 6-Arylbenzimidazo
[1,2-c]quinazoline  derivatives  as  tumor  necrosis  factor  alpha  (TNF-α)  production
inhibitors.  The  newly  synthesized  compounds  were  tested  for  their  in  vitroability  to
inhibit the lipolysaccharide (LPS) induced TNF- α secretion in the human promyelocytic
cell line HL-60. The compound 6-Phenyl-benzimidazo [1,2-c]quinazoline, coded as G1,
resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-
Arylbenzimidazo  [1,2-c]quinazoline  derivatives  may  have  a  potential  as  anti-
inflammatory agents [32].
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21. Suthakaran R et al., have been synthesized by condensing 2-methyl / phenyl / Chloro
methyl  disubstituted  benzooxazine-4-one  and 1-(2-  amino  ethyl  )–  4-  substituted
benzylidene-2-phenyl-1H–Imidazoles–5(4H)-one, gave 30 imidazolo quinazoline-4- one
derivatives.  All  the compounds have been  screened  for  their  antimicrobial  activities.
Most of the compounds have shown promising antibacterial, and antifungal activity [33].
22. Chan  Seong  Cheong  et  al., have  been  Studied  on  the  selective  reduction  of  1H-
Quinazoline-2,4-diones [34].
23. Ashraf  A.  Aly  et  al., have  been  synthesized  a  series  of  triazoloquinazolinones  and
benzimidazoquinazolinones  has  been  achieved  under  microwave  irradiation.  The
products  were  obtained  in  nearly  quantitative  yield  within  few  minutes  during  the
reaction  of  aromatic  aldehydes  with  5-amino-1(H)-1,2,4-triazole  (or  2-
aminobenzimidazole) and dimedone in DMF [35].
24. Periyasamy  Selvam  et  al., have  designed  and  synthesized  novel  2,3-disubtituted
quinazoline-4(3H)-ones by microwave technique  and characterized them by  spectral
analysis  &  synthesized  compounds  were  screened  for  cytotoxicity  and  for  antiviral
activity against influenza A [36].
25. Veerachamy  et  al.,  have  been  synthesized  a  series  of  3-benzyl-2-substituted-3H-
[1,2,4]triazolo[5,1-b]quinazolin-9-ones have been synthesized by the cyclo condensation
of  3-amino-2-benzylamino-3H-quinazolin-4-one with a  variety  of  one-carbon  donors.
The  compounds  were  evaluated  for  their  in  vivo  antihypertensive  activity  using
spontaneously  hypertensive  rats  (SHR).  While  all  the  test  compounds  exhibited
significant  antihypertensive  activity,3-benzyl-2-methyl-3H-[1,2,4]triazolo[5,1-
b]quinazolin-9-one exhibited antihypertensive activity more than the reference standard
prazocin [37].
26. Desai  N  C  et  al., have  been  reported  the  synthesis  and  characterization  of  new
quinazolines as potential antimicrobial agents [38]
27. Alagarsamy V  et al., A series of novel 1-substituted-4-benzyl-4H-[1,2,4]triazolo[4,3-
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a]quinazolin-5-ones were  synthesized by the cyclization of  2-hydrazino-3-benzyl-3H-
quinazolin-4-one with various  one-carbon donors.  When tested for  their  in vivo H1-
antihistaminic activity on guinea pigs, all the test compounds protected the animals from
histamine induced bronchospasm significantly [39].
28. Mistry  BD et  al., have  been  synthesized  6–bromo–2–alkyl/aryl–3{[phenyl
(phenyldiazenyl)methylene]amino}quinazolin–4(3H)–one  reported  their  antimicrobial
activity [40].
29. Mosaad  Sayed  Mohamed  et  al., have  been  synthesized a  series  of  new  5-(4-
chlorophenyl)-9-iodo-3-substituted-l,2,4-triazolo[4,3-c]quinazoline  and  2-  (4-
chlorophenyl)-6-iodo-4-substituted-quinazoline  was  prepared  via  several  synthetic
routes.  The synthesized  compounds  were  evaluated  as  anti-inflammatory  agents
through  the  carrageenin-induced  paw  edema  test.  The screening data revealed that
nine of the tested compounds shown activity comparable to indomethacin [41].
30. Terzio  Glu  et  al.,  Two  regioisomer  series,  2-(3-ethyl-4(3H)-quinazolinone-2-
ylmercaptoacetylhydrazono)-3-alkyl/3-aryl-5-methyl-4-thiazolidinones  (12-21)  and  2-
arylimino-3-(3-ethyl-4(3H)-quinazolinone-2-ylmercaptoacetyla-mino)-5-methyl-4-
thiazolidinones were synthesized and reported their anticonvulsant activity [42].
31. Sona Jantova et al., The antibacterial activity of ten series of substituted quinazolines
(157  derivatives)  against  bacterial  strains  Escherichia  coli CCM 3988,Pseudomonas
aeruginosa CCM 3955, Bacillus subtilis ATCC 6663 and Staphylococcus aureus CCM
3953 by micro  dilution assay was investigated.  The sensitivity of  the Gram positive
bacteria to the tested quinazolines was higher than that of Gram negative bacteria. The
most  effective  of  ten  quinazoline  structure  series  were  condensed
[1,2,4]triazoloquinazolines and 10H-[1,2,4]triazino[5,4-b]quinazolin-10-ones [43].
32. Archana  et  al., have  been  synthesized  derivatives  of  substituted  quinazolinonyl-2-
Oxo/thiobarbituric acid and their anticonvulsant activity was screened against maximal
electroshock (MES) and pentylenetetrazole (PTZ) models [44].
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33. Abdel Ghany Aly El-helby et al., A series of halogenated derivatives, 3-methyl, 3-ethyl
and  3-phenyl-6-mono  and  6,8-disubstituted-3H-quinazolin-4-one  derivatives  was  also
synthesized and evaluated for anticonvulsant activity.  Reduced anticonvulsant activity
was recorded. Phenobarbitone sodium was used as a reference [45].
34. Chioua  R  et  al.,  The  [4+2]  cycloaddition  between  2,4-diphenylpyrimidine  ortho-
quinodimethane and dimethyl acetylenedicarboxylate leads to 2,4-diphenylquinazoline-
6,7-dicarboxylate  .2,4-Diphenylfuro[3,4-g]quinazoline-6,8-dione   is  also  obtained  by
basic hydrolysis of  compound , followed by  the closure of the resulting diacid in acetic
anhydride [46].
35. Archana  et  al., have  been  synthesized  some  thiadiazolyl  and  thiazolidinonyl
quinazoline-4(3H)-ones  screened  them  for  anticonvulsant  activity  against  maximal
electroshock (MES) induced convulsions in animal models [47].
36. V.K.Pandey  et  al., have  been  synthesized  1,4-disubstituted  3-[3’-(2’-phenyl-4’-oxo-
quinazolinyl)]-2-azetidinones and reported their Antiferitility activity [48].
37. Piyush Kumar et al., have been synthesized 6- substituted 6- substituted-2-phenyl-3-(5-
substituted mercapto-1, 3, 4- thiadiazol-2-yl) quinazoline-4-(3H)-ones and reported their
anti tubercular activity [49].
38. H Mutlu Gençkal et al., reported new heterocyclic ligands, 2-(3-chloro-phenyl)-1, 2, 3,
4-tetrahydro-quinazoline-2-carbaldehyde oxime, (HL1) and 2-(3-bromo-phenyl)-1,2,3,4-
tetrahydro-quinazoline-2-carbaldehy-  de  oxime,(HL2),  and  Co(III)  complexes  of  their
open-chain tautomer,(HL1′ and HL2′), containing oxime, imine, and amine donor groups
resulting from the reactions with Co(II) ion have been synthesized and characterized by
spectral methods, elemental analysis, magnetic susceptibility, and thermal analysis (TG,
DTG, and DTA) techniques [50].
39. Jesus Sanmartín-Matalobos et al., Both experimental and computational studies were
undertaken to elucidate the formation process of 3-tosyl-1,2,3,4-tetrahydroquinazoline
from methanolic mother liquors of Pd(LBS)·3H2O, where LBS is the dianionic form of the
imine  ligand   N-{2-[(8-hydroxyquinolin-2-yl)   methyleneamino]benzyl}-4-
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thylbenzenesulfonamide.  Experimental  studies  have  shown  that  the
tetrahydroquinazoline is obtained by condensation of 2-tosyl amino methyl aniline and
formaldehyde, which come from the acid-catalyzed hydrolysis of the imine ligand LBS
and metal-mediated aerobic oxidation of methanol, respectively. Computational studies
have revealed relevant intermediates and key steps in the reaction pathway [51].
40. CAI  Suixiong et  al., Disclosed  are  novel  1-  (arylmethyl)  -5,  6,  7,  8-
tetrahydroquinazoline-2,  4-diones and  analogs  thereof,  represented  by the  Formula  I,
wherein Ar, A, B, R3-R6 are defined herein. Compounds having Formula I are PARP
inhibitors.  Therefore,  compounds  of  the  invention  may  be  used  to  treat  clinical
conditions that are responsive to the inhibition of PARP activity, such as cancer
[52]. 
4. MATERIALS AND METHODS
4.1.  Synthesis  of  tetrahydroquinazoline  derivatives. In  the  present  study  we  have
attempted  the  synthesis  of  tetrahydroquinazoline  derivatives  using  ethanol,
para amino phenol and aldehyde.
Table 1: Chemicals and Reagents 
S.No Chemicals/ Reagents Manufacturer
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1 Vanillin Sdfine chem. Ltd
2 Veratraldehyde Sdfine chem. Ltd
3 P-Tolualdehyde Sdfine chem. Ltd
4 3-Nitro Benzaldehyde Sdfine chem. Ltd
5 Dimethyl amine Sdfine chem. Ltd
6 Anisaldehyde Spectrum
7 Urea Merck
8 Ethanol Changshu Yangyuan
9 Para amino phenol Spectrum
10 Glacial acetic acid Merck
11 Methanol Qualigens
12 Diphenylamine Spectrum
13 Morpholine Sdfine chem. Ltd
14 Dimethyl Sulphoxide Merck
15 Silica gel G precoated Merck, Darmstadt
16 Aluminum sheets Germany
4.2. Instruments 
Table 2: Instrument List and Manufacturer
S.No Instrument Manufacturer
1 Digital electronic balance (BL- 220H) KE Roy Electronics ,Varanasi.
2 Melting point apparatus Shankar Scientific Chennai
3 FT-IR Spectroscopy Shimadzu FT 8300, Japan.
4 NMR Spectroscopy JEOL GSX 400, Japan.
5 Magnetic stirrer Remi equipments, Chennai.
6 Mass Spectroscopy JEOL GCmate, Japan.
7 UV Spectroscopy +2060 Spectrophometer
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4.3.SCHEME - I
R-CHO +2HNCONH2
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HN
RH
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O
O
H2N
H2N
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HO
BrH2N
CH3COOH
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N
H
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N
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HO
Br
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in DMF HCHO
N
NH
N
R
HO
Br
CH2R2
COMPOUND I
COMPOUND II
COMPOUND III
COMPOUND IV
Reflux 4 hrs
Reflux 5 hrs
R = Benzaldehyde   
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4.4. Synthesis of Compounds 1-4
Step – 1 Synthesis of 4-hydroxy-3-methoxy phenyl bis urea
A mixture of aldehydes (0.2 mol) and urea (0.4 mol) in absolute ethanol (100 ml) was heated
under  reflux for  4  hrs  in  such a  manner  that  moisture air  did  not  pass  into the reaction
mixture. Ethanol was removed by distillation and the residual solid was washed with water.
The crude product was dried in and recrystallized using dilute methanol [53].
Step – 2 Synthesis of 4-substituted-2-keto-1,2,3,4-tetrahyeroquinazoline-6-ol
A mixture of 4-hydroxy-3-methoxyphenyl-bis-urea (0.2mol) and p-amino phenol (0.2 mol)
were  dissolved  in  glacial  acetic  acid  (50  ml)  by stirring  and  heating slowly.  The  acidic
solution was subsequently heated under reflux for 5 hrs. The hot solution was cooled at room
temperature and poured into ice-cold water (250 ml) and stirring vigorously for half an hour.
It was filtered off and washed with water (3 × 25ml). The crude product was dried in vacuo
and recrystallized using diluted ethanol.
Step–3Synthesis of,4-Substiuted-2- P-bromophenyl imimo-1,2,3,4-trahydroquinazoline-
6-ol
A mixture of bromo aniline(0.2mol) and compound 2 in ethanol(30ml) containing 3-4 drops
of glacial acetic acid was heated for half an hour and left overnight at room temperature. The
solid product thus obtained was recrystallized with methanol.
Step–4   Synthesis of [(4-bromo phenylimino)-1,4-disubtituted-1,2,3,4-tetrahydro 
quinazoline-6-ol )].
A mixture  of  compounds  3  (0.01mol)  was  suspended  in  a  minimum quantity  (10ml)  of
dimethyl formamide (DMF). To this solution slight more than 0.01mol of formaldehyde and
various  secondary amines were added with vigorous stirring.  The reaction mixtures were
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heated on water bath for 20 minutes and left overnight. The product thus obtained was re-
crystallized from ethanol solvent [54]
4.5. Target Protein for Docking Study [55]
4.5.1. Polo-Like Kinase 1 (PLK1)
Antimitotics  form  the  basis  of  the  therapy  for  patients  with  both  solid  tumors  and
hematological  malignancies.  However,  current  antimitotic  drugs  affect  both  dividing  and
non-dividing cells. One of the emerging next generation antimitotic targets is Polo-like kinase
1 (PLK1). Among the four members of PLK family, PLK1 is the best characterized and it is
recognized to be a key component of the cell cycle control machinery with important roles in
the mitotic entry, centrosome duplication, bipolar mitotic spindle formation, transition from
metaphase to anaphase,  cytokinesis  and maintenance of genomic  stability.  PLK1 is often
over-expressed in many different tumor types and over-expression often correlates with poor
prognosis. As an antimitotic target, PLK1 is only expressed in dividing cells while it is not
expressed in differentiated postmitotic cells like neurons, where instead expression of PLK2
and PLK3 was reported. This indicates a potentially better safety profile for a PLK1 specific
inhibitor. Thus, PLK1 is thought to be a promising target for anti-cancer therapy and indeed
some PLK1 inhibitors are currently under evaluation in clinical trials.
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Active site chosen: Cys 67
Figure 2: Structure of PLK1
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Figure 3: Docking of compound 4a1 with PLK-1
Figure 4: Docking of compound 4a2 with PLK-1
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Figure 5: Docking of compound 4a3 with PLK-1
Figure 6: Docking of compound 4a4 with PLK-1
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Figure 7: Docking of compound 4a5 with PLK-1
Figure 8: Docking of compound 4a6 with PLK-1
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Figure 9: Docking of compound 4a7 with PLK-1
Figure 10: Docking of compound 4a8 with PLK-1
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Figure 11: Docking of compound 4a9 with PLK-1
Figure 12: Docking of compound 4a10 with PLK-1
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Figure 13: Docking of compound 4a11 with PLK-1
Figure 14: Docking of compound 4a12 with PLK-1
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5.BIOLOGICAL SCREENING
5.1. Hepato Protective  activity  of  synthesized tetra hydroquinazoline derivatives.
5.1.1. Animal Grouping and Maintenance
Male Wistar albino rats weighed 200 ± 20 g were utilized for this study. They were housed in
polypropylene cages under standard laboratory conditions (12-h light/ 12-h dark cycle, 21 ± 2
ºC, and relative humidity 55 %). The animals were given standard rodent pellets and water ad
labium.  The  rats  were  acclimatized  to  laboratory  condition  for  7  days  before  the
commencement  of  experiment.  The  hepatoprotective   study  was  carried  out  by  the
Chromosoft Infotech, Chennai as per the guidelines set by Organization for Economic Co‐
operation and Development (OECD) received from Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA NO. 8926/242/PAHR). 
On eighth day, the rats were sacrificed by overdose of anaesthetics, liver was separated and
used for estimation of biochemical parameters. 
5.1.2. Experimental procedure
In vitro study was done by using liver slice culture system following the protocol developed
by Wormser and Ben Zakine (1990) with slight modification. Rat liver was perfused heavily
by using Modified Hank’s Medium to remove all the blood clots. The liver was then cut into
small  square  slices,  weighing 5–6 mg,  and was  cultured  in  24  well  plates  (20–22 slices
weighing  about  100–120mg/well)  using  MEM  199  medium  supplemented  with  0.1-g/l
penicillin, 0.07-g/l streptomycin and 0.2% BSA. Liver slices were incubated in this condition
for 4 h at 370  in 95% O2 / 5% CO2. The medium was changed at 2 h, this time gap was
given to recover the shock from surgery.  The control  slices were kept in culture medium
only, ethanol (50 mg/ml) or ethanol plus 4a1 and 4a4 (2.5, 5.0 and 10.0 mg/ml) or ethanol plus
Silymarin (1.0, 2.0 and 3.0 mg/ml) were added to the incubation medium where mentioned.
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On  termination  of  incubation  at  4  h,  the  medium  was  collected  and  subjected  to  the
determination of SGOT and SGPT for the assessment of liver damage. 
The  liver  slices  from  different  incubations  were  separately  collected,  washed
repeatedly  and  then  homogenized  in  ice-cold  phosphate  (50mM,  pH  7.4)  buffer;  the
homogenate for each incubation was subjected to the estimation of lipid peroxidation.
Since co-treatment of 4a1  and 4a4 and alcohol for 12 days showed an optimum response, the
rest of the experiments were conducted for 12 days. To examine the efficacy of 4a1  and 4a4
with a standard drug for  liver  damage treatment,  I  have selected Silymarin,  at  a dose of
5mg/kg body weight for a single dose each day,  keeping control and 4a1  and 4a4  treated
group in a similar manner as described above. PBS using Potter Elvehjem homogenizer and
then subjected to differential centrifugation to separate cytosolic and microsomal fractions
according to the method. Protein estimation of the samples was done by using the method of
Lowry.
5.1.3. Serum Glutamate Oxaloacetate Transaminase 
Preparation of Diluted Serum: Fresh blood was allowed to clot and serum was collected.
Serum was then diluted with physiological saline in 1: 10 ratio. 0.2 – ml diluted serum was
taken in a test tube marked sample and to it 1 ml substrate buffer solution was added. It was
then mixed by inversion and incubated at 370 C for exactly 60 minutes. In a tube marked
blank 0.2 ml diluted serum was taken and to it 1 ml substrate buffer solution was added. It
was mixed well but no incubation was done [56-59].
In tubes marked standard different volumes of working standard solution were taken, viz. 0.1
ml, 0.2 ml, 0.3 ml. Then GDW was added in a way making the volume of each tube 2.2 ml.
To “sample”, “blank” and “standard” tubes 1 ml ketone reagent was added and kept at room
temperature for 15 minutes. To tubes “sample” and “blank” 5 ml in each and to “standard” 10
ml of 0.4 (N) NaOH was added,  mixed thoroughly and kept at  room temperature for 20
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minutes [60-62]. Optical densities of all the solutions were measured at 530 nm against the
blank solution. A standard curve was plotted with standard values and the unit of enzyme
present per 100 ml serum sample was calculated from curve [63]. 
5.1.4.  Serum Glutamate  Pyruvate Transaminase (SGPT)
In the tube marked sample 1 ml substrate buffer solution was taken and to it 0.2 ml diluted
serum (prepared as in  SGOT estimation)  was added,  mixed thoroughly by inversion and
incubated at 370 C for 60 minutes. In the tube marked blank 1 ml substrate buffer solution and
0.2 ml diluted serum were added but no incubation was done [63-68]. 1 ml ketone reagent
was added to both the tubes, which were then kept at room temperature for 15 minutes. 5 ml
0.4 (N) NaOH was added into each tube, mixed well and kept at room temperature for 20
minutes. Optical density of the experimental solution was read against the blank at 530 nm.
From the standard curve (plotted similarly in SGOT estimation), the unit of enzyme present
per 100 ml of serum was calculated [68-75].
5.1.5. Estimation of TBARS
The level of lipid peroxidation  as measured by TBARS was determined according to the
method  of  Buege  and  Aust  (1978).  Briefly,  1ml  of  the  microsomal  fraction  (containing
1mg/ml  protein)  was  mixed  with  2ml  of  the  TBA–TCA–HCl  reagent  and  vortexed
thoroughly. After heating for 15min in a boiling water bath, the samples were allowed to cool
and then centrifuged at 1000×g for 10min to remove the flocculants. The supernatant was
checked for TBARS content as a measure of lipid peroxidation.
5.1.6. Estimation of protein carbonyl content
Protein carbonyl content was determined according to Levine et al. (1990), using 0.8 ml of
the  cell  free  homogenate  (10%  homogenate  centrifuged  at  500×g  for  10min)  in  50mM
sodium phosphate buffer, pH 7.4. The protein was suspended with 0.5 ml of 2, 4, dinitro
phenylhydrazine and after washing in ethanol–ethyl acetate mixture (1:1), it was dissolved
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with  0.6  ml  of  guanidine–Protein  carbonyl  content  was  determined  from  the  extinction
coefficient at 362nm (ε = 22,000M−1 cm−1).
5.1.7. Catalase
Catalase activity was  assayed  by the method of  Aebi  (1984),  as  modified  by Kawamura
(1999). 20l of the cytosolic fraction was added to 980l assay buffer containing 50mM Tris–
HCl (pH 8.0), 9mM H2O2 and 0.25mM EDTA to constitute the assay volume of 1ml. The
decrease in absorbance of that assay mixture was recorded at 240 nm for 1min. The results
were expressed as unit catalase/mg protein.
5.1.8.  Measurement of PNP–UGT activity
p-Nitrophenol  (PNP) UGT activity was determined  by the method described by Bock as
modified  by  Viollon-  Abadie.  Briefly,  the  reaction  mixture  consisted  of  5mM  UDP-
glucuronic  acid,  1mM PNP and  microsomal  sample  without  (native)  or  with  (activated)
0.05% Triton X-100 in a final volume of 200 litre. The reaction mixture was incubated at 37
ᵒC for  30  min  and  then  stopped  by  the  addition  of  3.8  ml  of  NaOH  (0.1M).  The  PNP
glucuronidation  was  quantified  by  measuring  the  decrease  in  absorbance  at  405nm
(ε=18mM−1 cm−1).
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6. RESULTS AND DISCUSSION
The  synthesized  compound  4  [(4-Bromo  phenylimino)-1,4-disubstituted-1,2,3,4-
tetrahydroquinazoline-6-ol)]   was  used  for  the  synthesis  of  various  tetrahydroquinazoline
derivatives  was  shown  in  figure  15.  Further  docking  studies  was  done  with  different
substrates in R and R1 positions was shown in table 3.
Figure 15: Synthesized compound 4
Table 3: Various Substitutions of the Synthesized Compounds 4a1- 4a12
S.No Compound code R R1
1. 4a1
OCH3 HN O
2. 4a2
OCH3
N
CH3H3C
H
3. 4a3
N
CH3
CH3
HN O
4. 4a4
OH N
CH3H3C
H
5. 4a5
OCH3
OH
HN O
6. 4a6
OCH3 N
C6H5C6H5
H
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7. 4a7
N
CH3
CH3
N
C6H5C6H5
H
8. 4a8
N
CH3
CH3
N
C6H5C6H5
H
9. 4a9
OCH3
OH
N
CH3H3C
H
10. 4a10
OCH3
OH
N
C6H5C6H5
H
11. 4a11
OH HN O
12. 4a12
OH N
CH3H3C
H
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Table 4: List of Synthesized Compounds
S.No Compound
code Name Structure
1.
4a1
(E)-2-(4-bromophenylimino)-
4-(4-methoxyphenyl)-1-
(morpholinomethyl)-1,2,3,4-
tetrahydroquinazolin-6-ol N
HN
OH
O
N
O
N
Br
2. 4a2
(E)-2-(4-bromophenylimino)-
1-((dimethylamino)methyl)-4-
(4-methoxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol N
HN
OH
H3C
N
CH3
O
N
Br
3. 4a3
(E)-2-(4-bromophenylimino)-
4-(4-(dimethylamino)phenyl)-
1-(morpholinomethyl)-
1,2,3,4-tetrahydroquinazolin-
6-ol
N
HN
OH
O
N
N
N
Br
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4. 4a4
(E)-2-(4-bromophenylimino)-
1-((diphenylamino)methyl)-4-
(4-hydroxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol
N
NH
HO
OH
N
N
Br
5. 4a5
(E)-2-(4-bromophenylimino)-
4-(4-hydroxy-3-
methoxyphenyl)-1-
(morpholinomethyl)-1,2,3,4-
tetrahydroquinazolin-6-ol
N
HN
OH
O
N
N
Br
OH
OCH3
6. 4a6
(E)-2-(4-bromophenylimino)-
1-((diphenylamino)methyl)-4-
(4-methoxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol
N
HN
OH
O
N
N
Br
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7. 4a7
(E)-2-(4-bromophenylimino)-
4-(4-(dimethylamino)phenyl)-
1-((diphenylamino)methyl)-
1,2,3,4-tetrahydroquinazolin-
6-ol
N
HN
OH
N
N
N
Br
H3C CH3
8. 4a8
(E)-2-(4-bromophenylimino)-
1-((dimethylamino)methyl)-4-
(4-(dimethylamino)phenyl)-
1,2,3,4-tetrahydroquinazolin-
6-ol
N
HN
OH
N
N
CH3
CH3
N
Br
H3C CH3
9. 4a9
(E)-2-(4-bromophenylimino)-
1-((dimethylamino)methyl)-4-
(4-hydroxy-3-
methoxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol
N
HN
OH
OH
N
CH3
CH3
N
Br
OCH3
10. 4a10
(E)-2-(4-bromophenylimino)-
1-((diphenylamino)methyl)-4-
(4-hydroxy-3-
methoxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol
N NH
OH
O
OH
N
N
Br
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11. 4a11
(E)-2-(4-bromophenylimino)-
4-(4-hydroxyphenyl)-1-
(morpholinomethyl)-1,2,3,4-
tetrahydroquinazolin-6-ol N
HN
OH
O
N
OH
N
Br
12. 4a12
(E)-2-(4-bromophenylimino)-
1-((dimethylamino)methyl)-4-
(4-hydroxyphenyl)-1,2,3,4-
tetrahydroquinazolin-6-ol N
HN
OH
H3C
N
CH3
OH
N
Br
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Table 6: Application of lipinski rule of 5 to our ligand test set
S.No Ligand Molecular
weight
Number  of
Hydrogen
bond
acceptors
Number of
Hydrogen
bond
donors
Logp
(oct/wat)
Lipinski
Violations
1 4a1 523.431 7 2 5.024 2
2 4a2 481.394 6 2 5.178 1
3 4a3 536.474 7 2 5.069 2
4 4a4 591.509 6 3 8.036 2
5 4a5 539.43 8 3 4.309 1
6 4a6 618.579 6 2 8.481 2
7 4a7 605.536 6 2 8.453 2
8 4a8 494.437 6 2 5.223 1
9 4a9 497.393 7 3 4.46 0
10 4a10 546.798 0 0 9.497 2
11 4a11 509.404 7 3 4.488 1
12 4a12 446.367 6 3 4.642 0
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Chromatography Studies of Synthesized Compound
6.1. Thin Layer Chromatography
Thin Layer Chromatography or TLC is a solid-liquid form of chromatography here
the stationary phase is a polar absorbent and the mobile phase can be a single solvent or
Combination  of  solvents.  TLC  is  inexpensive  technique  and  quick  that  can  be  used  for
determine the number of components in a mixture, verify a substance’s identity, monitor the
process of a reaction, determine appropriate condition for column chromatography, analyze
the fractions obtained from column chromatography. 
6.1.1. Materials and Methods
1. Preparation of plates
 Silica gel G was mixed in a glass mortar to smooth consistency with the requisite
amount of water and slurry was quickly transferred to the spreader. The mixtures have been
spread over the plates in thickness of 0.2 mm and allow setting into a suitable holder and after
30 minutes, plates were dried at 120oC, for further activation of the absorbent.
2. Sample application
About 2 mm of absorbent from the edge of plate was removed to give sharply defined
edges.  2-5 µl  volumes of synthesized compounds were spotted with the help of capillary
tubes, just above 2 cm of the bottom of coated plates.
3. Development chamber
The chromatographic chamber was lined with filter paper dipping into mobile phase so
as to maintain the atmospheric saturation with solvent vapors in the chamber. The solvent
front was allowed to rise to distance of  about 12cm from the base line on the plate was
removed from the tank and allowed to dry in the air.
4. Solvent system
The choice of best developing solvent is one of the most important decisions in 
practical TLC by review of literature survey on by knowing nature of compounds, this 
solvent system used is toluene : ethyl acetate : formic acid (5:4:1). 
5. Detection of components 
The spots were visualized under Iodine chamber
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6.1.2.  Lipinski’s Rule
Lipinski's rule says that, in general, an orally active drug has no more than one violation of
the following criteria:
• Not more than 5 hydrogen  bond donors (nitrogen or oxygen  atoms with one or more
hydrogen atoms)
• Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
• A molecular weight under 500 Daltons
• An octane-water partition coefficient log P of less than 5. 
Note that all numbers are multiples of five, which is the origin of the rule's name.
6.1.3. Improvements
To evaluate drug likeness better, the rules have spawned many extensions, for example one
from a 1999 paper by Ghose et al, 
• Partition coefficient log P in -0.4 to +5.6 range 
• Molar refractivity from 40 to 130 
• Molecular weight from 160 to 480 
• Number of atoms from 20 to 70 
At Mol inspiration we believe that the strategy which leads to success is not a universal drug-
likeness score, but focus on particular drug classes and development of specific activity score
for each of these classes. The method we implemented uses sophisticated Bayesian statistics
to compare structures of representative ligands active on the particular target with structures
of  inactive  molecules  and  to  identify  substructure  features  (which  in  turn  determine
physicochemical properties) typical for active molecules. 
With  the  Mol  inspiration  virtual  screening  toolkit  miscreant one  can  easily  develop  a
screening engine for arbitrary target, provided that several active legends (in the extreme case
only single ligand) are known. With the trained model it is possible to screen large libraries
of hundreds of thousands of molecules in less than hour, to identify molecules with highest
chance to become active drugs or pesticides. 
Expert  system for  calculation of  drug likeness  score towards  GPCR ligands,  ion channel
modulators, kinase inhibitors, nuclear receptor ligands, protease inhibitors and other enzyme
targets based on Mol inspiration technology may be tested on-line. 
Table 6: Application of lipinski rule of 5 to our ligand test set
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S.No Ligand Molecular
weight
Number  of
Hydrogen
bond
acceptors
Number of
Hydrogen
bond
donors
Logp
(oct/wat)
Lipinski
Violations
1 4a1 523.431 7 2 5.024 2
2 4a2 481.394 6 2 5.178 1
3 4a3 536.474 7 2 5.069 2
4 4a4 591.509 6 3 8.036 2
5 4a5 539.43 8 3 4.309 1
6 4a6 618.579 6 2 8.481 2
7 4a7 605.536 6 2 8.453 2
8 4a8 494.437 6 2 5.223 1
9 4a9 497.393 7 3 4.46 0
10 4a10 546.798 0 0 9.497 2
11 4a11 509.404 7 3 4.488 1
12 4a12 446.367 6 3 4.642 0
Table 7: Molinspiration bio activity score of 4a1 – 4a12
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S.No
Ligand GPCR
ligand
Ion channel
modulator
Kinase
Inhibitor
Nuclear
Receptor
ligand
Protease
inhibitor
Enzyme
inhibitor
1 4a1 -0.11 -0.17 -0.35 -0.51 -0.34 -0.16
2 4a2 -0.10 -0.10 -0.36 -0.47 -0.36 -0.13
3 4a3 -0.08 -0.14 -0.30 -0.46 -0.31 -0.13
4 4a4 -0.03 -0.22 -0.25 -0.32 -0.22 -0.11
5 4a5 -0.10 -0.17 -0.32 -0.52 -0.36 -0.15
6 4a6 -0.07 -0.39 -0.33 -0.40 -0.22 -0.20
7 4a7 -0.07 -0.33 -0.32 -0.38 -0.24 -0.18
8 4a8 -0.07 -0.07 -0.32 -0.42 -0.33 -0.10
9 4a9 -0.09 -0.10 -0.33 -0.49 -0.38 -0.12
10 4a10 -0.07 -0.44 -0.39 -0.11 -0.10 -0.23
11 4a11 -0.08 -0.12 -0.34 -0.51 -0.31 -0.13
12 4a12 -0.07 -0.05 -0.34 -0.46 -0.33 -0.10
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6.1.4. SPECTRAL DATA
Table 8: IR Spectral Data of Compound 4a1
S.NO FREQUENCY MODE OF VIBRATION
1 1448 m CH3 bending
2 1405 m  O-H in plane bending and C-O Stretching
3 3215 m  N-H Stretching
4 1300-1253 s  Asymmetric C-O-C stretching
5 1339-1314 m  C-N stretching
6 589-514 C-Br stretching
7 1680 C=N stretching
8 1589 C=C stretching
9 976 s C-H out of plane bending
10 3070 C-H stretching
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 450.0
0.0
5
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25
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75
80
85
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95
100.0
cm-1
%T 
4a1
3380
3215
3070
2996
2974
2940
2843
2064
1705
1691
1670
1589
1508
1466
1448
1405
1372
1339
1314
1300
1253
1191
1177
1164
1122
1061
1030
976
851
820
803
614
589
535
514
Fi
gure 16: IR Spectrum of the Compound 4a1
 
Table 9: IR Spectral Data of Compound 4a2
S.NO FREQUENCY MODE OF VIBRATION
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1 1448 m CH3 bending
2 1405 m  (O-H in plane bending and C-O Stretching
3 3215 m (N-H Stretching)
4 1122 S (Asymmetric C-O-C stretching)
5 1314 m (C-N stretching)
6 589-514 C-Br stretching
7 1680 C=N stretching
8 1589 C=C stretching
9 820 – 803 s  C-H out of plane bending
10 3070 C-H stretching
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 450.0
0.0
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15
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cm-1
%T 
4a2
3787
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2842
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1691 1669
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977
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820
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514
Fig
ure 17: IR Spectrum of the Compound 4a2
Table 10: IR Spectral Data of Compound 4a3
S.NO FREQUENCY MODE OF VIBRATION
1 2810 m CH3 bending
52
2 1410 – 1400 m  (O-H in plane bending and C-O Stretching
3 3430 m - w(N-H Stretching)
4 1120 s (Asymmetric C-O-C stretching)
5 1314 m (C-N stretching)
6 593-509 C-Br stretching
7 1659 C=N stretching
8 1599 C=C stretching
9 834 – 815 s C-H out of plane bending
10 1227 – 1003 w C-H in plane bending
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 450.0
0.0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100.0
cm-1
%T 
4a3
3430
3077
2886
2850
2810
2636
2259
1898
1599
1573
1549
1526
1474
1443
1428
1410
1400
1365
1315
1257
1227
1177
1164
1120
1100
1068
1003
942
885
834
815
731
703
649
633
593
576
560
534
509
497
464
Figure 18: IR Spectrum of the Compound 4a3
Table 11: IR Spectral Data of Compound 4a4
S.NO FREQUENCY MODE OF VIBRATION
1 2810 m CH3 bending
2 1416 m  (O-H in plane bending and C-O Stretching
3 3392 m - w(N-H Stretching)
53
4 1120 s (Asymmetric C-O-C stretching)
5 1314 m (C-N stretching)
6 589 – 502 C-Br stretching
7 1659 C=N stretching
8 1594 C=C stretching
9 816 s C-H out of plane bending
10 1224 – 1005 w C-H in plane bending
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 450.0
0.0
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15
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40
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55
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95
100.0
cm-1
%T 
4a4
3392
3044
2542 2101 1934
1659
1594 1494
1459
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1311
1244
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1027
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748
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Figure 19: IR Spectrum of the Compound 4a4
Table 12: Mass Spectral Data of Compound 4a1 and 4a4
S.No. Compound Code Mass fragmentation pattern
1 4a1 523.13 (28.5%), 524.12 (97.12%), 522.13 (100%)
2 4a4
593.13 (36.2%), 592.13
54
(97.8%), 590.13
(100%)
Figure 20: Mass Spectrum of he Compound 4a1
55
Figure 21: Mass Spectrum of the Compound 4a4
Table 13:  NMR Spectral Data of Synthesized Compounds
COMPOUND 1H NMR (CDCL3-d, δppm)
4a1
2(d, 1H, 
-NH2), 4.62 
(S, 4H,   
-CH2)7.55-
7.92 (M, 4H, 
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Ar-CH), 7.2 
(S, 1H, -NH).
4a2
2.35(S, 3H, -CH 3), 4.62 (S, 2H,-CH2), 7.0(S, 1H, -NH), 7.3-7.98(M, 9H, 
Ar-H).
4a3
4.62(S, 2H, CH 2), 5(S, 1H, -OH), 6.8-7.98(M, 8H, Ar-H), 8.0(S, 1H, -NH), 
8.1(S, 1H, CH).
4a4
4.82(S, 2H, CH 2), 6.8-8.1 (M, 8H, Ar-H), 8.7(S, 1H, -NH), 8.2(S, 1H, CH), 
2.35(S, 6H, CH 3).
Figure 22: 1H NMR Spectrum of the Compound 4a1
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Figure 23: 1H NMR Spectrum of the Compound 4a2
Figure 24: 1H NMR Spectrum of the Compound 4a3
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Figure 25: 1H NMR Spectrum of the Compound 4a4
6.1.5. Study of  In vitro Hepatoprotective Activity.
The  resulting  liver  dysfunction  as  marked  by  the  increase  of  SGPT,  SGOT  and  ALP
activities.  4a1 and  4a4 decreased  the alcohol-induced  increase  of  SGPT, SGOT and  ALP
activities dose dependently.  However,  50 mg/kg bodyweight dose of 4a4 was found to be
most effective. This dose was therefore selected for next experiment on time-dependent effect
of  alcohol.  Treatment  of  alcohol  for  different  time periods  (0-35  days)  showed  a  linear
increase in the activities of the liver marker enzymes, SGPT, SGOT and ALP till 12 days and
at 15th day there was no significant additional effect over day 15.4a1 significantly decreased
alcohol-induced increase of enzyme activities, suggesting its hepatoprotective effect. 
UDP-glucuronosyl transferase (UGT) activity is known to prevent the generation of cellular
oxidative stress by glucuronidation and subsequent exclusion of harmful metabolites. UGT
therefore  plays  an  important  role  in  the  rescue  of  cellular  damage  due  to  stress.  This
prompted us to investigate UGT in some detail in the liver. Since 50 mg/kg body weight dose
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of 4a1 was found to be most effective in protecting liver damage, this dose was selected for
UGT-related studies. Alcohol treatment affected microsomal UGT activity that was evident
from  the  reduction  of  PNP-glucuronidation  and  4a1 prevented  the  deterioration  of
glucuronidation activity effectively.  It  could be seen from that alcohol treatment caused a
significant  decrease  (p  <  0.001)  in  UGT  gene  expression  while  co-treatment  with  4a1
protected the down regulation of this gene expression. 
Table 14: Effect of dosage on ALP activity
S.No Drug Optical Density
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1 Control 18 ± 0.9
2 Ethanol 59 ± 6.3
3 Ethanol+4a4 -2.5 42 ± 7.3
4 Ethanol+4a4-5.0 27 ± 1.9
5 Ethanol+4a4-10.0 29 ± 1.7
Figure 26: Effect of Dosage on ALP activity
Table 15:  Effect of dosage on SGOT activity
S.No Drug Optical Density
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1 Control 45 ± 4.2
2 Ethanol 135 ± 10.5
3 Ethanol+4a4-2.5 127 ± 11.83
4 Ethanol+4a4-5.0 65 ± 5.2
5 Ethanol+4a4-10.0 68 ± 4.8
Figure 27: Effect of Dosage on SGOT activity
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Table 16: Effect of dosage on SGPT activity
S.No Drug Optical Density
1 Control 22 ± 2.0
2 Ethanol 196 ± 15.3
3 Ethanol+4a4-2.5 136 ± 9.54
4 Ethanol+4a4-5.0 72 ± 4.6
5 Ethanol+4a4-10.0 81 ± 8.7
Figure 28: Effect of Dosage on SGPT activity
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Table 17: Measurement of PNP–UGT activity against synthesized compound 4a1
S.No Drug
PNP-UGT activity of non
activated microsomes
PNP-UGT activity of
activated microsomes
1 Control 61 ± 5.2 23 ± 1.1
2 Ethanol 40 ± 3.5 17 ± 0.9
3 Eth+4a1 67 ± 4.7 29 ± 1.2
Figure 29: Measurement of PNP–UGT activity against synthesized compound 4a1
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Table 18: Treatment of alcohol extract for different time periods (0–35 days)
S.No Days 0 7 14 21 28 35
1 Control 51 48 43 45 51 48
2 Ethanol 51 47 58 76 68 69
3 Ethanol+ 4a1 51 66 71 101 143 141
Figure 30: Treatment of alcohol extract for different time periods (0–35 days)
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